BOSTON, July 27, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. INZY, a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a price of $4.80…Read More
Inozyme Pharma Inc Announces Pricing of Public Offering of Common Stock Inozyme Pharma NASDAQINZY
